HC Wainwright Downgrades Caribou Biosciences to Neutral From Buy
MT newswire2026/10/08 10:2006:20 AM EDT, 10/08/2026 (MT Newswires) -- Caribou Biosciences (CRBU) has an average rating of overweight and mean price target of $10, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Is Leaving Exchanges. Here’s the Latest Development

Crypto Sell-Off Tied to Big IPOs, Says Ripple CEO

LOWE'S COMPANIES, INC. <LOW.N>: BARCLAYS CUTS TARGET PRICE TO $255 FROM $260